Buprenorphine Market

Buprenorphine Market Size (2023 to 2028)

The worldwide buprenorphine market growth is expected to reach USD 9.9 Billion by 2028 from USD 5.9 Billion in 2023, with a CAGR of 8.2% during the forecast period 2023 to 2028.

Buprenorphine, an FDA-approved medication, is utilized for various purposes such as managing acute and chronic pain as well as treating opioid dependence. It is part of agonist substitution treatment, a method that involves substituting a stronger opioid agonist (like heroin) with a substance such as buprenorphine or methadone for addiction treatment. Between 1999 and 2020, the US Centers for Disease Control and Prevention estimated that drug use resulted in approximately 494,492 deaths annually, with drug use disorders accounting for around 128,083 deaths each year.

As a response to these challenges, the Drug Addiction Treatment Act of 2016 was introduced, enabling physicians to offer office-based treatment for opioid addiction. This legislation grants physicians the ability to prescribe FDA-approved Schedule III, IV, or V "narcotic" medications to patients dealing with opioid addiction. As a result, the healthcare industry is witnessing a growing and promising market that is projected to generate substantial revenue in the coming years.

Market Drivers:

The major factors contributing to the growth of the market are the rise in opioid addiction cases, government initiatives towards innovation investments, and the rising geriatric population.

• Increasing opioid addiction or overdose cases to expand market share

The increasing availability and affordability of opioids have led to a rise in reported cases of opioid addiction, which is expected to drive the growth of the market. According to the World Drug Report, there was a 26 percent increase in global drug use among individuals aged 15-64, with approximately 284 million people using drugs in 2020. The younger generation has higher drug use rates compared to previous generations, particularly in Africa and Latin America where individuals under 35 account for the majority of those being treated for drug use disorders. Additionally, globally, around 11 million people abuse drugs through injection, which can lead to overdoses resulting from intentional or unintentional misuse of potent substances. The growing number of cases will fuel the expansion of the anti-drug market.

• Rising Healthcare Awareness Programs in developing nations

Government initiatives aimed at addressing substance dependency and drug abuse are anticipated to drive market growth. As an example, in April 2013, the Philippines, under President Rodrigo Roa Duterte, implemented collaborative anti-drug efforts involving both government and non-governmental organizations. These initiatives are designed to combat the issue of drug abuse and dependency.

• Rising old-age population will increase chronic disease-suffering patients

The growing elderly population is projected to fuel the demand for osteoarthritis cases, thereby driving market growth in the forecasted future. Rheumatoid Arthritis.org facts reported that approximately 1.3 million Americans and 1% of the global population are affected by rheumatoid arthritis, which represents a significant portion of osteoarthritis and gout cases.

Market Restraints:

The major factors restraining the market are side effects associated with the use of Buprenorphine, and a lack of licensed physicians for prescribing buprenorphine can hinder the market growth. According to a study published in the American Journal of Preventive Medicine in June 2018, the percentage of licensed physicians approved to prescribe buprenorphine for opioid use disorder was less than 4%.

Buprenorphine has certain effects similar to anticholinergics and may lead to central nervous system depression, hypotension, QT prolongation, and lower seizure threshold. Typical adverse effects associated with buprenorphine encompass nausea, vomiting, drowsiness, dizziness, headaches, memory impairment, sweating, dry mouth, constricted pupils, orthostatic hypotension, sexual side effects, and urinary retention.

The misuse of buprenorphine is another factor that can impede market growth. Despite being a partial opioid agonist with relatively low addiction potential, some individuals still misuse the drug. Buprenorphine tablets are sometimes crushed and either snorted or dissolved for intravenous use. In the United States, where buprenorphine is also available in sublingual form, concerns have been raised about diversion and abuse. To mitigate this, the sublingual formulation is combined with naloxone to prevent intravenous abuse.

Impact of COVID-19 on the Buprenorphine Market:

The global COVID-19 pandemic had a significant impact on businesses worldwide, disrupting their operations across various industries. To control the rapid spread of the disease, numerous countries implemented lockdown measures, resulting in the temporary closure of manufacturing facilities and a halt in production. The healthcare industry, in particular, encountered significant challenges as the outbreak caused widespread confusion and misinformation, placing immense pressure on hospitals and healthcare systems worldwide.

The global Buprenorphine drugs market is expected to face limitations in growth due to the impact of the COVID-19 pandemic. However, the pandemic's effect on bones and joints, causing pain, is anticipated to drive the growth of the Buprenorphine market. According to the Journal of Clinical Orthopedics and Trauma, the coronavirus can affect bones and joints, leading to increased research, development, and production of drugs.

Moreover, opium production worldwide increased by 7% from 2020 to 2021, reaching 7,930 tons, mainly driven by higher production in Afghanistan. Conversely, the global area under opium poppy cultivation decreased by 16 percent to 246,800 hectares during the same period. This shows the mixed impact of COVID-19 on the Buprenorphine market.

Report Coverage:

The market of buprenorphine is segmented and sub-segmented into applications, routes of administration, distribution channels, and regions.

By Application

• Analgesics
• Opioid Antagonist

Based on the application type, the opioid antagonist segment has dominated the market during the projection period. Buprenorphine, being an opioid antagonist, plays a crucial role in treating opioid addiction by blocking the effects of substances like heroin or oxycodone when taken at specific dosages. It is also effective in reducing withdrawal symptoms and is commonly used for detoxification purposes in individuals addicted to heroin, morphine, or other opiates, providing relief from withdrawal symptoms.

On the other hand, analgesics have also captured a significant market share, particularly when administered in combination with non-steroidal anti-inflammatory drugs. They have proven effective in managing chronic pain associated with cancer and other malignant tumors, as well as in providing acute pain relief, such as postoperative or trauma-related pain.

By Route Of Administration

• Oral
  • Sublingual
  • Buccal
• Parenteral routes
• Transdermal

Based on the route of administration type, the sublingual segment has dominated the market during the projection period. Buprenorphine can be administered through various routes, including oral forms such as sublingual tablets and buccal films.

Parenteral routes, such as subdermal or subcutaneous implants, as well as intravenous (IV) or intramuscular (IM) injections, are also available for buprenorphine administration.

Additionally, transdermal administration is commonly employed alongside these methods, particularly for chronic pain management where a transdermal patch is considered an effective option.

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on distribution channels, the hospital pharmacies segment dominated the market in 2022. Hospitals serve as central hubs for patient care and complex surgical procedures. The increasing preference of patients for hospitals as screening venues, the rise in the number of hospitals in emerging economies, and the strong network of hospitals in developed countries. Growing awareness among the general population and the implementation of screening programs in healthcare facilities further contribute to market growth.

On the other hand, the online, and retail pharmacies segment, is projected to hold an equal share of the global market. This can be attributed to the increasing penetration of the internet, easy access to nearby stores, and the wide range of products available on e-commerce platforms, offering convenience and variety to consumers.

By Region

• North America
• Europe
• Asia-Pacific
• The Middle East & Africa
• Latin America

By region, North America dominates the market due to the high prevalence of opioid and heroin abuse. In 2016, an estimated 11.4 million people in the United States misused prescription opioids, and there was an increase in heroin-related deaths from 13,219 in 2016 to 15,594 in 2017. The region continues to face a significant challenge with overdose deaths, driven largely by the non-medical use of fentanyl. In 2021, preliminary estimates indicate more than 107,000 drug overdose deaths in the United States, surpassing the number of nearly 92,000 deaths recorded in 2020. This anticipates the upcoming trend for the buprenorphine market.

Europe also holds a significant share of the overall industry and is expected to witness substantial expansion in the coming years.  Eastern and South-Eastern Europe, as well as Central Asia, show high rates of individuals undergoing treatment for opioid use disorders. The region is witnessing increased awareness about these disorders among the general population, coupled with growing healthcare spending, which will contribute to market expansion.

The rest of the world, including Latin America and the Middle East & Africa, will witness a rise in the number of patients suffering from opioid dependency and is also expected to experience substantial growth, with a noteworthy CAGR in the forecasted period.

Key Market Players:

Some of the notable key market players include Rusan Pharma, Resonance-labs, Sun Pharma, Unichemlabs Noramco, Siegfried, Faranshimi, Johnson Matthey, Mallinckrodt, Sanofi, Mocind, and Sinopharm.

Recent Market Developments:

1. In May 2022, Sun Pharma Ltd. revealed that its wholly-owned subsidiary will be launching a new oral lipid-lowering drug, Bempedoic Acid, in India. This medication is designed to reduce levels of low-density lipoprotein (LDL) cholesterol. The drug will be introduced in the market under the brand name Brillo.

2. In June 2021, Purdue Pharma LP has recently announced that the U.S. Food and Drug Administration has accepted and filed their abbreviated new drug application for the vial dosage form of nalmefene hydrochloride injection. This particular formulation is intended to be used for the treatment of opioid overdose.